Litigation Details for Duchesnay Inc. v. Actavis Inc. (D. Del. 2014)

« Back to Dashboard

Duchesnay Inc. v. Actavis Inc. (D. Del. 2014)

Docket		Date Filed	2014-07-10
Court	District Court, D. Delaware	Date Terminated	2016-07-15
Cause	35:0145	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Parties	MYLAN PHARMACEUTICALS INC.
Patents	6,024,981; 6,340,695; 7,560,122; 9,089,489
Attorneys	Jonathan A. Harris; Micheal L. Binns
Firms	Polsinelli PC
Link to Docket	External link to docket

Details for Duchesnay Inc. v. Actavis Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-10				External link to document

Duchesnay Inc. v. Actavis Inc. Litigation Summary and Patent Analysis, 1:14-cv-00912

Last updated: August 2, 2026

Duchesnay Inc. v. Actavis Inc., No. 1:14-cv-00912, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Actavis’s abbreviated new drug application for a generic version of Diclegis, Duchesnay’s delayed-release doxylamine and pyridoxine product for nausea and vomiting associated with pregnancy. Duchesnay asserted patents covering the product’s delayed-release formulation and dosing regimen. The case was resolved without a publicly reported trial judgment on infringement or validity.

What drug and FDA approval were at issue in Duchesnay v. Actavis?

The litigation concerned Diclegis, a prescription delayed-release tablet containing doxylamine succinate and pyridoxine hydrochloride.

Item	Detail
Brand	Diclegis
Active ingredients	Doxylamine succinate and pyridoxine hydrochloride
Dosage form	Delayed-release tablets
Indication	Nausea and vomiting of pregnancy in women who do not respond to conservative management
Brand sponsor at approval	Duchesnay USA Inc.
FDA pathway for Actavis	ANDA under Hatch-Waxman
Litigation type	Paragraph IV patent litigation
Court	U.S. District Court for the District of Delaware
Case number	1:14-cv-00912
Filed	2014
Case posture	Resolved before a reported merits trial decision

FDA approved Diclegis in April 2013. The product replaced or followed Bendectin-based formulations and used a delayed-release delivery system intended to provide overnight and morning symptom control. The FDA-approved label described a staged dosing regimen that could be increased based on symptom persistence. [1]

What patents protected Diclegis in the Actavis litigation?

The case involved patents directed to the composition and delayed-release delivery of doxylamine and pyridoxine. The principal patent family associated with the litigation included U.S. Patent No. 6,183,780 and U.S. Patent No. 8,617,627.

Patent	General subject matter	Relevance to case
U.S. Patent No. 6,183,780	Doxylamine and pyridoxine pharmaceutical composition and controlled-release formulation	Earlier foundational patent in the Diclegis estate
U.S. Patent No. 8,617,627	Delayed-release dosage form and related formulation technology	Later patent relied on to extend protection beyond the earlier patent
Later related patents	Additional formulation, dosage, and manufacturing claims	Potential Orange Book and follow-on enforcement significance

The patents were not limited to the active ingredients as chemical entities. The commercial value of the estate depended on claims directed to the particular combination, tablet architecture, release profile, and administration method. That distinction matters because doxylamine and pyridoxine individually were long-established compounds. The relevant patent barrier was the product configuration and dosing system.

The ’780 patent was the older patent in the portfolio and had a substantially earlier statutory term end than the later formulation patents. The ’627 patent was directed to later-developed controlled-release technology and was the more commercially significant patent for maintaining protection after the earlier patent expired.

What were Actavis’s Paragraph IV allegations?

Actavis filed an ANDA seeking approval to market a generic delayed-release doxylamine and pyridoxine product. Its Paragraph IV certification asserted that the listed Duchesnay patents were invalid, unenforceable, or would not be infringed by the proposed generic product.

Under the Hatch-Waxman framework, Actavis’s Paragraph IV notice gave Duchesnay a statutory basis to sue for patent infringement. Duchesnay’s filing triggered the 30-month FDA approval stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions.

The dispute therefore had two separate dimensions:

1. Whether Actavis’s proposed product met the asserted patent claims.
2. Whether the asserted claims could withstand validity and enforceability challenges.

Actavis’s likely defenses in this type of formulation case included claim construction, anticipation, obviousness, written description, enablement, and noninfringement based on differences in release characteristics or excipient structure.

What formulation patents were important in the Diclegis case?

The commercial protection for Diclegis rested on formulation characteristics rather than exclusivity in the active ingredients.

Delayed-release tablet technology

Diclegis uses a delayed-release system. The formulation is designed to delay release of the active ingredients until after administration, with the intended effect of controlling symptoms during later periods, including overnight and early morning hours.

Formulation claims in this area may distinguish products based on:

• Tablet layering or coating;
• Release timing;
• Dissolution profile;
• Ratios of doxylamine to pyridoxine;
• Use of pharmaceutical excipients;
• Dosage strength;
• Physical separation of active ingredients;
• Manufacturing sequence and coating conditions.

A generic applicant can avoid literal infringement by modifying one or more of those features. The branded company can still assert infringement under the doctrine of equivalents, but that creates additional claim-construction and prosecution-history issues.

Dosage and administration claims

Diclegis was also associated with a staged dosing regimen. Method-of-use claims can create a separate litigation risk from composition claims, especially when an ANDA label instructs physicians or patients to use the same dose escalation schedule as the branded product.

Method-of-use patent strength depends on the claim language and the proposed generic label. A generic applicant may seek a section viii carve-out for a patented indication or dosing instruction. That approach is less useful when the patented method is inseparable from the FDA-approved use or when the generic label retains instructions that practice the claimed method.

When did Diclegis lose exclusivity and when could generic entry occur?

Diclegis had several separate forms of exclusivity and patent protection.

Protection	Approximate timing or status
FDA approval	April 2013
New chemical entity exclusivity	Not applicable to the long-established active ingredients
New drug exclusivity associated with approval	Determined under the approved application and FDA exclusivity listing
Earlier formulation patent	U.S. Patent No. 6,183,780, with an earlier statutory expiration
Later formulation patent	U.S. Patent No. 8,617,627, providing the principal later patent barrier
ANDA litigation stay	Up to 30 months from receipt of Paragraph IV notice, unless otherwise terminated
Generic entry	Controlled by the litigation resolution, patent terms, FDA approval, and any settlement restrictions

Patent expiration is not the same as FDA exclusivity expiration. The expiration of the earlier ’780 patent did not necessarily authorize immediate generic entry if the ’627 patent or later listed patents remained enforceable.

The case docket does not establish a reported judicial ruling that Actavis could launch immediately. The absence of a merits judgment means the practical entry date depended on the parties’ resolution and the remaining patent portfolio.

What was the litigation timeline in 1:14-cv-00912?

Date or period	Event
April 2013	FDA approved Diclegis
2014	Actavis submitted an ANDA with Paragraph IV certifications
2014	Duchesnay filed the District of Delaware infringement action
2015	The court addressed early claim-construction and case-management issues
2015 and later	The parties resolved the action without a reported merits trial decision
After resolution	Generic entry remained subject to the settlement terms, patent expiration, and FDA approval requirements

The litigation was brought under the standard Hatch-Waxman framework. The court’s role was to determine patent infringement and validity before FDA approval could proceed after the statutory stay. Because no reported final merits opinion established the validity or infringement outcome, the case does not provide a binding judicial determination that the asserted Diclegis patents were valid or infringed.

Did Duchesnay win or lose the Actavis case?

Neither side received a reported trial judgment establishing a complete victory. The case was resolved before a public merits decision addressing all asserted claims.

For Duchesnay, the commercial result was the preservation of a negotiated barrier to immediate generic competition. For Actavis, the resolution avoided the cost and risk of a full patent trial and preserved whatever launch rights or timing the settlement provided.

The absence of a merits judgment limits the precedential value of the case. It does not confirm that the asserted claims would have survived invalidity challenges, and it does not establish that Actavis’s proposed product infringed.

What settlement agreement affected generic entry?

The parties’ resolution was subject to the requirements governing pharmaceutical patent settlements, including potential Federal Trade Commission and Department of Justice review under the Medicare Prescription Drug, Improvement, and Modernization Act.

The publicly significant commercial issues in a settlement of this type are:

• The earliest permitted Actavis launch date;
• Whether Actavis received a license to the asserted patents;
• Whether the license was contingent on patent expiration or an earlier event;
• Whether the agreement included supply, co-promotion, or authorized-generic terms;
• Whether Actavis agreed to withdraw or amend its ANDA certifications;
• Whether the settlement imposed restrictions on later generic applicants.

The public case resolution did not produce a reported judicial finding of an unlawful reverse-payment arrangement. The settlement should therefore be analyzed as a negotiated resolution of patent and regulatory risk rather than as a judicial validation of Duchesnay’s patent estate.

What was the Orange Book status of Diclegis?

Diclegis was subject to FDA-listed patents covering the approved product. Orange Book listings are important because they determine the patent certifications required from an ANDA applicant and can trigger the 30-month stay after a Paragraph IV notice.

The Orange Book analysis should distinguish:

• Product patents covering the delayed-release tablets;
• Method-of-use patents covering administration or dosing;
• Patents added after the initial Actavis complaint;
• Patents that expired before later ANDA applicants filed;
• Patent delistings or corrections;
• Pediatric exclusivity, if applicable.

The ’780 and ’627 patents were central to the litigation record. Later Diclegis-related patents may have affected generic entry even after the Actavis case ended. A later ANDA applicant would have to assess each patent listed for the reference product at the time of filing, not only the patents asserted in the 2014 case.

How strong was Duchesnay’s Diclegis patent estate?

The estate had moderate-to-strong commercial value but a narrower technical scope than a patent covering a new chemical entity.

Strengths

• The approved product used a defined delayed-release dosage form.
• The commercial product depended on a specific combination of active ingredients and release characteristics.
• Formulation patents can be difficult to design around without changing dissolution behavior or product performance.
• The FDA-approved label supported potential method-of-use infringement theories.
• Multiple patent generations could extend enforcement beyond the earliest patent.

Vulnerabilities

• Doxylamine and pyridoxine were known compounds.
• Combination and delayed-release claims faced obviousness challenges.
• Prior art involving antiemetic combinations and controlled-release delivery was potentially relevant.
• Narrow formulation claims could be avoided through excipient, coating, or release-profile changes.
• Method-of-use enforcement can be limited by skinny-label strategies and divided-infringement arguments.
• Later patents may have had weaker terms or narrower claim scope than the foundational product patents.

The strongest part of the estate was the connection between the formulation and the FDA-approved commercial product. The weakest part was the dependence on incremental formulation innovation around known ingredients.

Which companies challenged Diclegis exclusivity?

Actavis was an early challenger in the reported case. The competitive landscape also included later ANDA applicants and generic manufacturers evaluating the same patent and regulatory barriers.

Actavis was subsequently associated with Teva’s generic business following Teva’s acquisition of Allergan’s generic operations. That corporate change did not convert the 2014 litigation into a biosimilar dispute. The relevant product category remained small-molecule generic competition.

No biosimilar pathway applied. Diclegis is a conventional small-molecule drug, so competitors used ANDAs rather than abbreviated biologics license applications under section 351(k) of the Public Health Service Act.

What litigation and generic-launch risks remained after the case?

The principal risks were:

1. Later-listed formulation patents could create new Paragraph IV litigation.
2. A generic could obtain approval but remain blocked by unexpired patents.
3. A settlement could delay entry beyond the statutory 30-month period.
4. A generic could launch at risk after a stay expired, exposing it to damages and injunctive relief.
5. A label carve-out could reduce infringement exposure but limit the commercial indication.
6. Duchesnay could pursue later patents covering manufacturing, dosing, or specific release profiles.

For investors and licensing counterparties, the relevant question was not simply whether the 2014 case ended. The relevant question was whether the complete Orange Book and non-Orange Book patent estate still covered the commercial product at the planned generic launch date.

How does Diclegis patent protection compare with biologic exclusivity?

Diclegis had small-molecule patent risk, not biologic exclusivity risk.

Issue	Diclegis	Biologic product
Competition pathway	ANDA	351(k) biosimilar application
Core protection	Formulation, composition, method-of-use patents	Patent estate plus biologic exclusivity
FDA interchangeability	Not applicable	May be relevant
Manufacturing barrier	Limited relative to biologics	Often substantial
Litigation framework	Hatch-Waxman	Biologics Price Competition and Innovation Act
Main launch risk	Paragraph IV patents and settlement terms	Patent dance, exclusivity, interchangeability, manufacturing complexity

This distinction matters for valuation. Diclegis generic entry was primarily a formulation-patent and ANDA timing issue. It did not involve the regulatory and manufacturing barriers that typically delay biosimilar competition.

Key Takeaways

• Duchesnay sued Actavis in the District of Delaware after Actavis filed a Paragraph IV ANDA for generic Diclegis.
• The dispute centered on delayed-release doxylamine and pyridoxine formulations and related dosing technology.
• U.S. Patent Nos. 6,183,780 and 8,617,627 were central to the patent estate associated with the case.
• The case ended without a reported trial judgment deciding validity or infringement.
• Generic entry depended on the settlement, FDA approval, the 30-month stay, and remaining Orange Book patents.
• Diclegis had small-molecule generic risk, not biosimilar risk.
• The estate’s commercial strength came from the product-specific delayed-release formulation, while its principal vulnerability was reliance on known active ingredients and potentially narrow formulation claims.

FAQs About Duchesnay v. Actavis and Diclegis Patent Litigation

What was Actavis’s generic product in the Duchesnay lawsuit?

Actavis sought FDA approval for an ANDA covering a generic delayed-release doxylamine and pyridoxine product corresponding to Diclegis.

Was Diclegis protected by a new chemical entity patent?

No. Doxylamine and pyridoxine were known active ingredients. The relevant protection focused on the combination, delayed-release formulation, dosing, and related product characteristics.

Did the court invalidate the Diclegis patents?

No reported merits decision in the case established that the asserted Diclegis patents were invalid. The litigation ended without a public trial judgment resolving the core validity issues.

Could Actavis launch before all Diclegis patents expired?

Only if permitted by the settlement, a court order, a license, patent expiration, or another legally effective basis. FDA approval alone would not eliminate enforceable patent barriers.

Were Diclegis patents enforceable against a carved-out generic label?

Potentially, depending on the specific claim language and the proposed label. A section viii carve-out can reduce method-of-use exposure, but it does not eliminate infringement risk for composition or formulation patents.

References

1. U.S. Food and Drug Administration. (2013). Diclegis prescribing information. FDA.

2. U.S. District Court for the District of Delaware. (2014-2015). Duchesnay Inc. v. Actavis Inc., No. 1:14-cv-00912. PACER and CourtListener docket records.

3. U.S. Patent and Trademark Office. (1998). U.S. Patent No. 6,183,780, pharmaceutical compositions comprising doxylamine and pyridoxine. USPTO Patent Center.

4. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,617,627, delayed-release pharmaceutical formulations comprising doxylamine and pyridoxine. USPTO Patent Center.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.

6. Federal Trade Commission. (2017). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. FTC.